Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_1
3
75%
Ph phase_2
1
25%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

completed375%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

NCT01327612
completedphase_1

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

NCT01940172
completedphase_1

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

NCT00630786
withdrawnphase_1

Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

NCT01017822

Clinical Trials (4)

Showing 4 of 4 trials
NCT01327612Phase 2

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Completed
NCT01940172Phase 1

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

Completed
NCT00630786Phase 1

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

Completed
NCT01017822Phase 1

Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4